Just over a month ago, at the BIO virtual conference, Pfizer Commercial Director John Young said the company was not thinking of a return on investment for its rapidly developing COVID-19 vaccine. Instead, he said, “finding medical solutions to this crisis” was a Pfizer priority. But now that the company …
Read More »